CompletedNot Applicable

Prevalence of Lipodystrophy Syndrome and Its Role as Cause of Metabolic Disturbances

Spain276 participantsStarted 2016-02

Plain-language summary

To evaluate the prevalence of lipodystrophy syndrome in patients receiving currently available antiretroviral drugs, and the prevalence of associated metabolic syndrome in HIV-infected patients with a previous diagnosis of lipodystrophy syndrome, according to the severity of fat accumulation and antiretroviral drug use.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * HIV infection * Older than 18 years * Receiving first or second antiretroviral regimen or * Previous evaluation and classification of lipodystrophy syndrome Exclusion Criteria: * Pregnancy * Diagnosis of hypothyroidism, Cushing's syndrome or prolonged intake of corticosteroids or hormones before inclusion * Patients who had received antiretroviral drugs known to produce fat disturbances (for lipodystrophy prevalence objective)

What they're measuring

Prevalence of metabolic syndrome as defined by the NCEP-ATP III (National Cholesterol Education Programme-Adult Treatment Panel III)

Timeframe: 3 months

Prevalence of lipodystrophy syndrome as defined by changes in fat by DXA

Timeframe: 6 meses

Trial details

NCT IDNCT02614027

SponsorAsociacion para el Estudio de las Enfermedades Infecciosas

Sponsor typeNETWORK

Study typeOBSERVATIONAL

Primary completion2018-02

View on ClinicalTrials.gov More Lipodystrophy trials